Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin-tazobactam for Ventilator-associated Pneumonia in ESBL-E Carriers
NCT04276480Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Feb 2022
- Primary completion
- Apr 2024
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of piperacillin + tazobactam in ventilator-associated pneumonia (VAP), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Mortality in Intensive Care Unit at 28 days. Started Feb 2022; status: completed.
02
Drugs
piperacillin + tazobactam
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT04276480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276480.